CMD LLC wins AU$1 million grant award from FightMND
Singapore, April 18 -- Collaborative Medicinal Development LLC (CMD) is a privately-held biopharmaceutical company developing innovative therapies for neurodegenerative diseases. CMD has announced that it was awarded a AU$1 million grant from FightMND to support a Phase 2 study of CuATSM for treatment ALS (amyotrophic lateral sclerosis), also known as Lou Gehrig'sdisease, or Motor Neuron Disease (MND).
In 2016, FightMND helped to support the phase 1 clinical trial of CuATSM where it was given to MND patients as a therapeutic for the first time. The primary objective, as per any phase 1 trial, was to assess safety and tolerability of the drug and, if possible, identify a dose that could be taken to the next round of testing. By assessing ...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.